Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know

Bone

Volumn 49, Issue 1, 2011, Pages 56-65

  Allen, Matthew R ^a   Burr, David B ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

Anti resorptives; Mechanics; Microdamage; Remodeling; Turnover

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BIOMECHANICS; BONE DENSITY; BONE INJURY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CORTICAL BONE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENERGY ABSORPTION; FATIGUE; HUMAN; LOW DRUG DOSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SINGLE DRUG DOSE; TRABECULAR BONE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BIOMECHANICS; BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; FRACTURES, BONE; HUMANS;

EID: 79958703451     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2010.10.159     Document Type: Review

References (96)

1. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
2. Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Investig 1996, 97:2692-2696.
3. Allen M.R., Erickson A.M., Wang X., Burr D.B., Martin R.B., Hazelwood S.J. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 2010, 86:67-71.
4. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38(5):617-627.
5. Leu C.T., Luegmayr E., Freedman L.P., Rodan G.A., Reszka A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006, 38:628-636.
6. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
7. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51:2187-2195.
8. Bonnick S., Saag K.G., Kiel D.P., McClung M., Hochberg M., Burnett S.M., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006, 91:2631-2637.
9. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20:141-151.
10. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005, 353:898-908.
11. Borah B., Ritman E.L., Dufresne T.E., Jorgensen S.M., Liu S., Sacha J., et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37:1-9.
12. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Investig 1997, 100:1475-1480.
13. Recker R.R., Weinstein R.S., Chesnut C.H., Schimmer R.C., Mahoney P., Hughes C., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 2004, 15:231-237.
14. Recker R.R., Delmas P.D., Halse J., Reid I.R., Boonen S., Garcia-Hernandez P.A., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008, 23:6-16.
15. Allen M.R., Kubek D.J., Burr D.B. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010, 25:98-105.
16. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
17. Allen M.R., Burr D.B. Mandible matrix necrosis in beagle dogs after 3years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008, 66:987-994.
18. Allen M.R., Follet H., Khurana M., Sato M., Burr D.B. Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 2006, 79:255-261.
19. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
20. Allen M.R., Turek J.J., Phipps R.J., Burr D.B. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate. Bone 2011, 49:128-132.
21. Silverman S.L., Watts N.B., Delmas P.D., Lange J.L., Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007, 18:25-34.
22. Chesnut C.H., Harris S.T. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteoporos Int 1993, 3(Suppl 3):S17-S19.
23. Rossini M., Gatti D., Zamberlan N., Braga V., Dorizzi R., Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994, 9:1833-1837.
24. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
25. Rossini M., Gatti D., Girardello S., Braga V., James G., Adami S. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis. Bone 2000, 27:119-122.
26. Bagger Y.Z., Tanko L.B., Alexandersen P., Ravn P., Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7years after treatment withdrawal. Bone 2003, 33:301-307.
27. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296:2927-2938.
28. Grey A., Bolland M.J., Wattie D., Horne A., Gamble G., Reid I.R. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009, 94:538-544.
29. Gray A., Bolland M.J., Wattie D., Horne A., Gamble G., Reid I.R. Prolonged anti-resorptive activity of zoledronate - a randomized controlled trial. J Bone Miner Res 2010, 25(10):2251-2255.
30. Lund T., Abildgaard N., Delaisse J.M., Plesner T. Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol 2010, 151(1):92-93.
31. Wronski T.J., Dann L.M., Qi H., Yen C.F. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 1993, 53:210-216.
32. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover following discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23:1689-1697.
33. Tamura Y., Miyakoshi N., Itoi E., Abe T., Kudo T., Tsuchida T., et al. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res 2001, 16:541-549.
34. Bare S., Recker S., Recker R., Kimmel D. Influence of alendronate on periosteal and endocortical bone formation in the illium of osteoporotic women. J Bone Miner Res 2005, 20:SA414-SA.
35. Recker R., Coble T., Burshell A., Lombardi A., et al. Effect of alendronate and estrogen replacement on periosteal bone formation in postmenopausal women. J Bone Miner Res 2001, 16:1176.
36. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
37. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
38. Lafage M.H., Balena R., Battle M.A., Shea M., Seedor J.G., Klein H., et al. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study. J Clin Invest 1995, 95:2127-2133.
39. Yoshida Y., Moriya A., Kitamura K., Inazu M., Okimoto N., Okazaki Y., et al. Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 1998, 13:1011-1022.
40. Feher A., Koivunemi A., Koivunemi M., Fuchs R.K., Burr D.B., Phipps R.J., et al. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone 2010, 46:203-207.
41. Vajda E.G., Hogue A., Griffiths K.N., Chang W.Y., Burnett K., Chen Y., et al. Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats. J Bone Miner Res 2009, 24:231-240.
42. Iwata K., Li J., Follet H., Phipps R.J., Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independent of resorption in rat femur and tibia. Bone 2006, 39:1053-1058.
43. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144:5441-5449.
44. Bikle D.D., Morey-Holton E.R., Doty S.B., Currier P.A., Tanner S.J., Halloran B.P. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J Bone Miner Res 1994, 9:1777-1787.
45. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645.
46. Seeman E. To stop or not to stop, that is the question. Osteoporos Int 2009, 20:187-195.
47. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006, 21:292-299.
48. Diab T., Allen M.R., Burr D.B. Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporos Int 2009, 20:647-652.
49. Miller P.D., Bolognese M.A., Lewiecki E.M., McClung M.R., Ding B., Austin M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
50. Allen M., Burr D. Skeletal microdamage: less about biomechanics and more about remodeling. Clin Rev Bone Miner Metab 2008, 6:24-30.
51. Allen M.R., Burr D.B. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone. BoneKEy 2007, 4:49-60. http://www.bonekey-ibms.org/cgi/content/abstract/ibmske;4/2/49.
52. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
53. Allen M.R., Iwata K., Sato M., Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006, 39:1130-1135.
54. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
55. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003, 18:512-520.
56. Burr D. Microdamage and bone strength. Osteoporos Int 2003, 14:67-72.
57. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
58. Mashiba T., Hui S., Turner C.H., Mori S., Johnston C.C., Burr D.B. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif Tissue Int 2005, 77:180-185.
59. Mori S., Burr D.B. Increased intracortical remodeling following fatigue damage. Bone 1993, 14:103-109.
60. Bentolila V., Boyce T.M., Fyhrie D.P., Drumb R., Skerry T.M., Schaffler M.B. Intracortical remodeling in adult rat long bones after fatigue loading. Bone 1998, 23:275-281.
61. Cardoso L., Herman B.C., Verborgt O., Laudier D., Majeska R.J., Schaffler M.B. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009, 24:597-605.
62. Verborgt O., Gibson G.J., Schaffler M.B. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 2000, 15:60-67.
63. Li J., Mashiba T., Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001, 69:281-286.
64. Burr D.B., Martin R.B. Calculating the probability that microcracks initiate resorption spaces. J Biomech 1993, 26:613-616.
65. Follet H., Li J.L., Phipps R.J., Hui S., Condon K., Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 2007, 40:1172-1177.
66. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
67. Stepan J.J., Burr D.B., Pavo I., Sipos A., Michalska D., Li J., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007, 41:378-385.
68. Chapurlat R.D., Arlot M., Burt-Pichat B., Chavassieux P., Roux J.P., Portero-Muzy N., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007, 22:1502-1509.
69. Allen M.R., Gineyts E., Leeming D.J., Burr D.B., Delmas P.D. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int 2008, 19:329-337.
70. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008, 19:1343-1354.
71. Tang S.Y., Zeenath U., Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007, 40:1144-1151.
72. Iwata K., Allen M.R., Phipps R., Burr D.B. Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate than with risedronate. Bone 2006, 38:42.
73. O'Neal J.M., Diab T., Allen M.R., Vidakovic B., Burr D.B., Guldberg R.E. One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation. Bone 2010, 47:241-247.
74. Siegmund T., Allen M.R., Burr D.B. Can deterministic mechanical size effects contribute to fracture and microdamage accumulation in trabecular bone?. J Theor Biol 2010, 265:202-210.
75. Hoshaw S.J., Cody D.D., Saad A.M., Fyhrie D.P. Decrease in canine proximal femoral ultimate strength and stiffness due to fatigue damage. J Biomech 1997, 30:323-329.
76. Yeni Y.N., Fyhrie D.P. Fatigue damage-fracture mechanics interaction in cortical bone. Bone 2002, 30:509-514.
77. Jansen J.P., Bergman G.J., Huels J., Olson M. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 2009, 25:1861-1868.
78. Imai K., Ohnishi I., Matsumoto T., Yamamoto S., Nakamura K. Assessment of vertebral fracture risk and therapeutic effects of alendronate in postmenopausal women using a quantitative computed tomography-based nonlinear finite element method. Osteoporos Int 2009, 20:801-810.
79. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22:149-157.
80. Keaveny T.M., Hoffmann P.F., Singh M., Palermo L., Bilezikian J.P., Greenspan S.L., et al. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 2008, 23:1974-1982.
81. Lewiecki E.M., Keaveny T.M., Kopperdahl D.L., Genant H.K., Engelke K., Fuerst T., et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009, 94:171-180.
82. Turner C.H., Burr D.B. Basic biomechanical measurements of bone - a tutorial. Bone 1993, 14:595-608.
83. Allen M.R., Burr D.B. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 2008, 19:95-99.
84. Ding M., Day J.S., Burr D.B., Mashiba T., Hirano T., Weinans H., et al. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int 2003, 72:737-744.
85. Day J.S., Ding M., Bednarz P., van der Linden J.C., Mashiba T., Hirano T., et al. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 2004, 22:465-471.
86. Wang X., Allen M.R., Burr D.B., Lavernia E.J., Jeremic B., Fyhrie D.R. Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone. Bone 2008, 43:775-780.
87. Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 2009, 27:1288-1292.
88. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
89. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577-2586.
90. Muller R., Hannan M., Smith S.Y., Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 2004, 19:1787-1796.
91. Shahnazari M., Yao W., Dai W., Wang B., Ionova-Martin S.S., Ritchie R.O., et al. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 2010, 46:1267-1274.
92. Hansen U., Zioupos P., Simpson R., Currey J.D., Hynd D. The effect of strain rate on the mechanical properties of human cortical bone. J Biomech Eng 2008, 130:011011.
93. Zioupos P., Hansen U., Currey J.D. Microcracking damage and the fracture process in relation to strain rate in human cortical bone tensile failure. J Biomech 2008, 41:2932-2939.
94. Diab T, Wang J, Reienwald S, Guldberg RE, Burr DB. Effects of the Combination treatment 1 of raloxifene and alendronate on the biomechanical properties of vertebral bone. J Bone Miner Res in press. Epub ahead of print Aug 4. doi:10.1002/jbmr.197.
95. Johnell O., Scheele W.H., Lu Y., Reginster J.Y., Need A.G., Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:985-992.
96. Forwood M.R., Burr D.B., Takano Y., Eastman D.F., Smith P.N., Schwardt J.D. Risedronate treatment does not increase microdamage in the canine femoral-neck. Bone 1995, 16:643-650.